Zacks Downgrades Intrexon Corp to Underperform (XON)
Intrexon Corp (NYSE:XON) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research note issued to investors on Wednesday. They currently have a $19.70 price target on the stock. Zacks‘s price target would suggest a potential downside of 5.20% from the company’s current price.
Intrexon Corp (NYSE:XON) traded down 0.82% during mid-day trading on Wednesday, hitting $20.61. 146,349 shares of the company’s stock traded hands. Intrexon Corp has a 1-year low of $13.13 and a 1-year high of $38.50. The stock’s 50-day moving average is $23.11 and its 200-day moving average is $23.66. The company’s market cap is $2.071 billion.
Intrexon Corp (NYSE:XON) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. The company had revenue of $11.80 million for the quarter, compared to the consensus estimate of $9.39 million. Analysts expect that Intrexon Corp will post $-0.49 EPS for the current fiscal year.
Intrexon Corporation is engaged in the business of synthetic biology. Using the Company’s suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (NYSE:XON) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.